- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The HFrEF Standard of Care
An expert in the management of heart failure discusses the standard of care for patients with reduced ejection fraction.
EP: 1.Heart Failure Clinical and Economic Burden
EP: 2.The Progressive Nature of Heart Failure
EP: 3.Link Between LVEF, NT-ProBNP and Cardiac Remodeling
EP: 4.Improved Understanding of Heart Failure
EP: 5.Treatment Goals for Patients With Heart Failure
EP: 6.The HFrEF Standard of Care
EP: 7.Heart Failure Management Unmet Needs
EP: 8.Utilization Management Strategies for Appropriate Treatment
EP: 9.Challenges in the Management of HFpEF
EP: 10.Differences in Standard of Care: HFpEF vs HFrEF
EP: 11.Ensuring Timely and Appropriate Access to Therapy
EP: 12.Differences in Economic Burden: HFpEF and HFrEF
EP: 13.PROVE-HF Trial Overview
EP: 14.PARAGON-HF Trial Overview
EP: 15.Recent Findings from the PARALLAX Study
EP: 16.Promising Findings From the TOPCAT Study
EP: 17.Differences in Leading Treatments for Heart Failure
EP: 18.When to Add an SGLT2 Inhibitor to Treatment Regimen
EP: 19.Heart Failure Sites of Care
EP: 20.How Approved Agents Will Change the Standard of Care
EP: 21.Heart Failure Management During COVID-19
John McMurray, MBChB: In patients with heart failure and reduced ejection fraction, we have what some people have recently been calling the 5 alive: the 5 pharmacological approaches that improve survival. These can be given in 4 pills. First is a renal angiotensin system blocker. Today we would couple that with a neprilysin inhibitor, and those 2 treatments can be prescribed in 1 pill: sacubitril-valsartan. Next is a beta-blocker with a mineral corticoid receptor antagonist or aldosterone antagonist. Most recently, the fifth of those pharmacological approaches is an SGLT2 inhibitor. In addition, we have other drugs that improve symptoms and reduce the risk of heart failure hospitalization, but they don’t reduce mortality. Good examples of that would be ivabradine, digoxin, and most recently, a treatment called vericiguat. We may see also new ideas about intravenous iron very shortly, so that may also be added to that list. We also have devices that we use selectively in certain patients that improve survival, and these are implantable cardioverter variation defibrillators and cardiac resynchronization therapy. We’ve got a wealth of life-saving treatments, and a wealth of treatments that improve symptoms and reduce hospital admission.
Discharge Timing and Associations With Outcomes Following Heart Failure Hospitalization
October 9th 2025A retrospective multicenter study found that patients with heart failure discharged by noon had higher short- and long-term mortality and increased early readmission rates compared with afternoon discharges.
Read More
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Racial, Ethnic Disparities May Impact Age Differences at First Heart Failure Hospitalization
September 4th 2025Social determinants of health were associated with a younger age of first hospitalization for heart failure in Black and Hispanic patients when compared with Asian and White patients.
Read More
